Abstract
Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have